Membrane transport proteins associated with drug resistance expressed in human melanoma.
- 1 December 1995
- journal article
- Vol. 147 (6), 1545-52
Abstract
Melanoma cells often display a multidrug-resistant phenotype, but the mechanisms involved are largely unknown. We have studied here the recently identified transport-associated proteins, MRP and LRP, and the well-known drug resistance marker P-glycoprotein using a panel of 16 human melanoma cell lines and 71 benign and malignant melanocytic tissue samples. By flow cytometry and immunohistochemistry, expression of P-glycoprotein was not detectable on the protein level in the 10 cell lines analyzed, although by reverse transcriptase polymerase chain reaction, MDR-1 gene expression was demonstrated in 2 of 10 cell lines. In addition, immunohistology revealed P-glycoprotein expression in only 1 of 71 melanocytic lesions. In contrast, MRP was detected in a subset of melanoma cell lines by reverse transcriptase polymerase chain reaction and immunohistology (4 of 10). LRP expression was observed in 8 of 10 melanoma cell lines by immunochemistry and in 10 of 10 by reverse transcriptase polymerase chain reaction. Furthermore, MRP was detected immunohistologically in almost 50% of primary and metastatic melanoma specimens, although no significant differences were found between metastases taken before or after chemotherapy. Expression of LRP was detected in a subset of nevi with nevus cells exhibiting up to 25% positive LRP reactivity. In 13 of 21 primary melanomas and 23 of 37 metastases, more than 25% of tumor cells were stained by the LRP-56 monoclonal antibody. Particularly in the group of metastases with more than 50% of LRP-positive cells, 7 of 11 of the metastases had been previously exposed to chemotherapeutic drugs. Although the expression of membrane transport proteins may explain only the chemoresistance toward lipophilic, natural compounds and not resistance against alkylating agents, the lack of P-glycoprotein expression after chemotherapeutic treatment and the significant expression of MRP and LRP in melanoma cells provide first insights into the drug-resistant phenotype in melanoma. Additional studies analyzing the role of MRP and LRP in chemoresistance of melanoma are warranted.This publication has 29 references indexed in Scilit:
- P-glycoprotein expression in primary and metastatic malignant melanomaBritish Journal of Dermatology, 1995
- Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivityCancer, 1994
- Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumoursThe Journal of Pathology, 1993
- Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell LineScience, 1992
- Mechanisms of Multidrug Resistance in Cancer TreatmentActa Oncologica, 1992
- Therapy for cutaneous melanoma: An updateJournal of the American Academy of Dermatology, 1990
- Expression of Multidrug Resistance Gene in Human CancersJNCI Journal of the National Cancer Institute, 1989
- Monoclonal antibody JSB‐1 detects a highly conserved epitope on the P‐glycoprotein associated with multi‐drug‐resistanceInternational Journal of Cancer, 1988
- Mechanism of multidrug resistanceBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1988
- Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodiesNature, 1985